SS
PRLD icon

SBI Securities’s Prelude Therapeutics PRLD Stock Holding History

SBI Securities’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117 Sell
22
-2,619
-99% -$11.4K ﹤0.01% 3471
2026
Q1 		$9.03K Sell
2,641
-100
-4% -$262 ﹤0.01% 1773
2025
Q4 		$7.95K Hold
2,741
– – ﹤0.01% 1816
2025
Q3 		$3.95K Hold
2,741
– – ﹤0.01% 2142
2025
Q2 		$2.22K Hold
2,741
– – ﹤0.01% 2337
2025
Q1 		$2.1K Hold
2,741
– – ﹤0.01% 2270
2024
Q4 		$3.5K Buy
+2,741
New +$3.64K ﹤0.01% 2066

Other funds holding PRLD

New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

SBI Securities's PRLD Position: Q2 2026 in Review

SBI Securities reduced its Prelude Therapeutics (PRLD) stake by 99% in Q2 2026, selling an estimated $11.4K and leaving 22 shares worth $117. The position accounts for ﹤0.01% of the portfolio, ranked #3471.

SBI Securities first reported a position in PRLD in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.03K in Q1 2026. 6 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • SBI Securities held 22 shares of Prelude Therapeutics worth $117 as of Q2 2026.
  • SBI Securities sold 2,619 Prelude Therapeutics shares in Q2 2026, an estimated $11.4K.
  • Prelude Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3471 holding.
  • SBI Securities first reported a position in Prelude Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Prelude Therapeutics position peaked at $9.03K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.